Trial · NCT07524374
SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy
NCT07524374, Phase 2, Not yet recruiting, Zhigang Li
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy. Trials, record NCT07524374. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07524374
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy
- NCT number
- NCT07524374
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 33 participants, estimated
- Lead sponsor
- Zhigang Li
- Conditions
- ESCC
- Interventions
- SHR-1701+ liposomal irinotecan (II)
- First posted
- 2026-04-13
- Last updated
- 2026-04-13
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate | through study completion, an average of 12 weeks | Objective response rate (ORR) defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR). |
| Secondary | Disease Control Rate | through study completion, an average of 12 weeks | Disease Control Rate (DCR) defined as the proportion of patients whose best overall response is CR, PR, or SD. |
| Secondary | Progression-Free Survival | through study completion, an average of 6 months | Progression-Free Survival defined as the time from the first dose to the first documented disease progression as assessed by the investigator per RECIST version 1.1, or the time from enrollment to death from any cause, whichever occurs first. |
| Secondary | Oearall survival | through study completion, an average of 12 months | Overall Survival (OS) Defined as the time from the first dose to death from any cause. |
| Secondary | Safty | Documented from the time of signing the informed consent form until the end of the safety follow-up period (Day 90 after the last dose) or the initiation of a new anti-cancer therapy, whichever occurs first. | Adverse Events (AEs): Incidence and severity (including whether they are serious adverse events or immune-related adverse events), with severity graded according to NCI-CTCAE version 6.0; |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07524374
GET https://conductscience.org/api/trials/v1/NCT07524374/registered